What Is PROCEPT BioRobotics Corporation (PRCT) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, PROCEPT BioRobotics Corporation's intrinsic value is estimated at $10.07, suggesting the stock is overvalued at its current price of $19.31. With 10 out of 11 models flagging downside (-47.9% average return), the market may be pricing in unsustainable growth. Notably, PWERM sees the most upside at +14.3% (fair value: $22.08), while ML-RIV is the most conservative at -98.5% ($0.29). The spread between these extremes — +112.9% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About PRCT?
11 of 13 models are currently active for PRCT. Of these, 1 model suggests upside while 10 models suggest overvaluation. The Bayesian DCF estimates PRCT's intrinsic value at $8.40, implying -56.5% downside from the current price. See which stocks rank higher →
How Does PRCT Rank in Surgical & Medical Instruments & Apparatus?
Among 117 Surgical & Medical Instruments & Apparatus stocks, PRCT ranks #40 by Quality of Company score. CirclFi's QOC score of 7.1/10 evaluates 32 fundamental signals. A score of 7.1 indicates above-average quality.
See all Most Undervalued Surgical & Medical Instruments & Apparatus Stocks →
PROCEPT BioRobotics Corporation operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is PRCT a Value Trap?
CirclFi's Value Trap algorithm assigns PRCT a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for PROCEPT BioRobotics Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, PROCEPT BioRobotics Corporation's fundamental quality profile registers 7.1/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +112.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PRCT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PRCT's 11 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad